Structural & Drug Screening (SDS)

项目总结/摘要（结构和药物筛选） 在之前的CCSG更新中，结构生物学（SB）和高通量筛选（HTS）都是 作为新的共享资源（SR）获得批准和供资。在项目期间，独立工作人员代表 为密歇根大学综合癌症中心（UMCCC）成员提供经常协调的服务 提高癌症相关项目的效率和影响。这次合作展示了 从项目启动就开始合作。工作人员代表和UMCCC领导人认为，工作人员代表的合并是一个 这是一种自然发展的方式，也是一种让成员从这些重要资源中获得最大利益的方式。支持下 来自UMCCC高级领导层的Janet Smith博士于2015年加入了联合主任Vince Groovy博士，当时 他们正式将员工代表合并为一个单位。在此过程中，将药物化学（MC）添加到SR中 以满足癌症研究人员的现有需求。2016年，UMCCC批准建立一个全面的 统一的设施，结构和药物筛选（SDS）SR。SDS SR使UMCCC成员能够使用 先进的基于结构的药物设计和/或无偏见的HTS策略，以确定化学物质， 通过里程碑式的研究计划推进，从而实现高效和有效的发现， 精准肿瘤药物的开发; UMCCC的战略目标。这是通过使用三个 服务学科，其中每一个是由一个经验丰富的教师领导：SB，博士的指导下，指导。 Smith博士指导下的HTS和Andrew白色博士指导下的MC。SR的 有凝聚力的活动、服务和流程为UMCCC成员带来了四个主要好处：I）项目提前 沿着转化管道，从基础科学发现到早期癌症药物发现; II）项目 管理人员指导研究人员有效和高效地使用与其需求相匹配的适当服务; III） 一个综合的团队方法为研究人员提供了一个完整的，“一站式”的专业知识， 研究人员通过精简行政支助结构节省了费用。

PROJECT SUMMARY/ABSTRACT (STRUCTURE AND DRUG SCREENING) In the previous CCSG renewal, Structural Biology (SB) and High-Throughput Screening (HTS) were both approved and funded as new Shared Resources (SRs). During the project period, the independent SRs frequently coordinated services for University of Michigan Comprehensive Cancer Center (UMCCC) members to increase the efficiency and impact of cancer-related projects. This collaboration demonstrated the benefit of working together from project initiation. The SRs and UMCCC leaders viewed the amalgamation of the SR as a natural progression and a way for members to receive maximum benefit from these vital resources. With support from UMCCC Senior Leadership, Janet Smith, PhD was joined by Co-Director Vince Groppi, PhD in 2015 when they formally merged the SRs into one unit. During this process, Medicinal Chemistry (MC) was added to the SR to meet existing needs of cancer researchers. In 2016, UMCCC approved the establishment of a comprehensive unified facility, the Structure and Drug Screening (SDS) SR. The SDS SR enables UMCCC members to use advanced structure-based drug design and/or nonbiased HTS strategies to identify chemical matter that can be advanced through a milestone-driven research plan resulting in efficient and effective discovery and development of precision oncology medicines; a strategic goal of UMCCC. This is accomplished by use of three service disciplines, each of which is guided by an experienced faculty leader: SB, under the direction of Dr. Smith; HTS, under the direction of Dr. Groppi, and MC under the direction of Andrew White, PhD. The SR's cohesive activities, services and processes yield four key benefits to UMCCC members: I) projects are advanced along the translational pipeline, from basic science discoveries into early cancer drug discovery; II) a project manager guides researchers in the effective and efficient use of appropriate services matched to their needs; III) an integrated team approach provides researchers a complete, `one-stop' set of expertise for the duration of their projects; and IV) researchers accrue cost savings from a streamlined administrative support structure.